Covid-19 has shown its effects throughout the globe. It was an inevitable situation and since its outbreak, every country expected the virus to reach its borders sooner or later. Some countries felt a far much serious impact of the virus as their health system, economy, and the market crashed abysmally. In the case of Pakistan, however, the situation was somewhat different. Pakistan did suffer from the pandemic but better decisions, better steps, and comprehensive planning was the main reason why Pakistan tackled this condition in a much better way. Of significance has been the coordination between federal and provincial government authorities for the pandemic emergency measures.
The rate at which the virus affected Pakistan was surprisingly lower than what was being expected. In 2 years, approximately 1.3 million patients have been confirmed COVID-19 positive in Pakistan. Amongst COVID-19 positive patients, 2.2% suffered death; the more vulnerable age group of greater than50 years were mainly affected. The death rate in Pakistan is also comparable to the global average death rate (2.0%) among COVID-19 positive cases. The highest peak of positivity percentage was observed in April-2021 with 11.63 %. After vaccination drive in the country, a total of 133 million subjects have received single or two (02) doses of vaccine, of which 56 million people have been fully vaccinated in the country by 12th December 2021.
In general, Pakistan did fairly better than many other countries, not only did we tackle the pandemic with sensible and calculated steps, Pakistan also emerged as one of the hubs for the clinical research and development related to COVID healthcare management.
Different Types of Trials:
Pakistan has contributed to conducting clinical trials of various kinds to help develop vaccines and drugs for the prevention and treatment of COIVD-19. Ministry of Health in Pakistan and the Drug Regulatory Authority of Pakistan have invested great efforts in the development of vaccines. As of now, fifteen (15) clinical trials of different phases (Phase I-III) have been approved by DRAP and almost 61 clinical trial sites have been approved by DRAP across the country.